arrow
M

Mariangela Figini

istituto nazionale dei tumori
H指数:32
被引数:3,655

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production

通过工艺开发和良好生产规范生产,对首个同类抗肿瘤IgE抗体药物MOv18进行理化性质和功能评价

MABS
IF7.3
2025-01-201
OA
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial
2023-07-258
OAAI
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes
2022-11-1937
OA
FIRST-IN-HUMAN PHASE I CLINICAL TRIAL EVALUATING INTRAPERITONEAL ADMINISTRATION OF MOV19-BBZ CAR T CELLS IN PATIENTS WITH ALPHA FOLATE RECEPTOR-EXPRESSING RECURRENT HIGH GRADE SEROUS OVARIAN CANCER
2021-11-103
OA
Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2
2021-06-1016
OAAI
Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
2020-06-0115
OAAI
Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
2018-10-1568
OAAI
An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE
2018-10-0823
OAAI